Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 7/20 | 0.61 |
| ▸ | THRA | P10827 | 6/20 | 0.61 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959433 | 0.84 | FKBP1A (0.57) | THRBTHRAFKBP1ANPSR1RXFP1 | |
| SCHEMBL13895737 | 0.83 | PTPN7 (0.53) | MCL1THRBTHRAPTPN7MAPT | |
| SCHEMBL5514421 | 0.83 | PTPN7 (0.53) | MCL1THRBTHRAPTPN7MAPT | |
| SCHEMBL585812 | 0.81 | MCL1 (0.72) | MCL1THRBTHRAFKBP1APTPN7 | |
| SCHEMBL30025591 | 0.81 | MCL1 (0.72) | MCL1THRBTHRAFKBP1APTPN7 | |
| SCHEMBL18488071 | 0.79 | THRB (0.53) | MCL1THRBTHRAPTPN7MAPT | |
| SCHEMBL9945969 | 0.79 | KDM4E (0.58) | FKBP1AMAPTL3MBTL1CARM1KDM4E | |
| SCHEMBL5514977 | 0.79 | AGER (0.51) | MCL1THRBTHRAPTPN7MAPT | |
| SCHEMBL3385737 | 0.78 | PPARD (0.69) | MCL1 | |
| Acetic Acid SCHEMBL28288847 | 0.78 | MCL1 (0.68) | MCL1THRBTHRAFKBP1APTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3053911-A1 | ADIPONECTIN RECEPTOR-ACTIVATING COMPOUND | The University of Tokyo (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2016-07-28 | — | — | US | disclosed |
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2000066573-A2 | OXA COMBINATORIAL LIBRARY, PRODUCTION AND USE THEREOF | CEREP (FR) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | ADIPOR1, ADIPOR2, CCKAR | MCL1 4522/4885THRB 105/4885THRA 78/4885 |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | MCL1 3847/4885THRB 1717/4885THRA 2302/4885 |
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | ADIPOR1, ADIPOR2, CCKAR | MCL1 4522/4885THRB 105/4885THRA 78/4885 |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | MCL1 3842/4885THRB 1924/4885THRA 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.